Key Highlights
- Arcturus and Thermo Fisher announced a July 2, 2026 manufacturing and clinical-services collaboration to prepare ARCT-032 for Phase 3 and potential commercial supply, contingent on positive Phase 2 data.
- The 12-week Phase 2 study of ARCT-032 began dosing in the first quarter of 2026 after earlier 28-day cohorts, including a 15 mg dose, were reported as safe and well tolerated.
- First-quarter 2026 revenue fell to $2.1 million from $29.4 million a year earlier as CSL Seqirus-linked collaboration revenue declined; net loss widened to $27.0 million.
- Cash and restricted cash stood at $213.4 million as of March 31, 2026, which Arcturus says funds operations into the second quarter of 2028.
Arcturus Therapeutics (NASDAQ:ARCT) has enlisted Thermo Fisher Scientific to help manufacture and eventually commercialize ARCT-032, its inhaled mRNA candidate for cystic fibrosis, ahead of a planned Phase 3 program. The San Diego company, whose approved KOSTAIVE COVID-19 vaccine is commercialized through partners, reported shrinking collaboration revenue and a wider quarterly loss even as cash reserves last into 2028.
Why Arcturus Is Back in Investors' Crosshairs
Arcturus Therapeutics Holdings Inc. (ARCT) drew fresh attention on July 2, 2026, when it disclosed a strategic collaboration with Thermo Fisher Scientific centered on ARCT-032, its investigational inhaled mRNA therapy for cystic fibrosis. The tie-up is a manufacturing and clinical-development arrangement rather than a licensing deal: Thermo Fisher will supply manufacturing, clinical-research and commercial-readiness services through its Accelerator Drug Development platform, while Arcturus retains control of the science.
Arcturus has spent the past two years pivoting away from a COVID-19 vaccine business that once generated most of its revenue and toward a smaller, rare-disease pipeline anchored by ARCT-032 and ARCT-810 for ornithine transcarbamylase (OTC) deficiency. That pivot has cut costs sharply but also shrunk the collaboration revenue that used to offset research spending, leaving the company more reliant on cash reserves while the programs mature.
A Platform Company Built on Two mRNA Technologies
Founded in 2013 and based in San Diego, Arcturus is built around LUNAR lipid-mediated delivery, STARR self-amplifying mRNA (sa-mRNA), and in-house manufacturing. Its most significant product is KOSTAIVE, built on the ARCT-154 sa-mRNA construct and described by the company as the first self-amplifying mRNA COVID-19 vaccine in the world to receive full regulatory approval, a milestone corroborated by a December 2023 Nature analysis. In January 2026 the U.K.'s MHRA approved KOSTAIVE for adults 18 and older. Commercialization runs through CSL Seqirus globally and the ARCALIS venture with Meiji in Japan, which is preparing a two-dose KOSTAIVE vial for the 2026-2027 season. Arcturus also develops a pandemic influenza vaccine under a BARDA contract.
Arcturus Therapeutics (ARCT) and the Thermo Fisher Manufacturing Pact
The Thermo Fisher collaboration is narrowly scoped but structurally important. Thermo Fisher will provide Phase 3 manufacturing and related clinical-research services for ARCT-032; if the ongoing Phase 2 study is positive, Arcturus expects to run Phase 3 through Thermo Fisher's PPD clinical-research business. Separately, subject to eventual regulatory approval, Thermo Fisher would receive exclusive commercial manufacturing rights under a future commercial agreement still to be negotiated. Arcturus has not disclosed upfront payments, milestones or royalties tied to the pact. CEO Joseph Payne said the deal aligns with "efficiently advancing our cystic fibrosis program into Phase 3 and preparing for potential commercial supply." The arrangement remains contingent on the Phase 2 study reading out favorably; no Phase 3 start date has been set.
The CF program has cleared several safety checkpoints: a third 28-day cohort of ARCT-032 at 15 mg in four Class I CF adults showed no new safety issues, and a safety review committee cleared advancement into a 12-week Phase 2 study. That study, enrolling up to 20 Class I CF participants at a 10 mg dose, began ahead of schedule in the first quarter of 2026, tracking lung function (ppFEV1, lung clearance index), quality-of-life measures and HRCT imaging. On ARCT-810, the FDA gave clarity in a March 2026 Type C meeting on a pediatric pathway, and the program is broadening to address late-onset adults and severe pediatric cases with no option besides liver transplantation, ahead of an end-of-Phase-2 meeting due in the second half of 2026.
Revenue Concentration Is Shifting, and Shrinking
For the three months ended March 31, 2026, total revenue was $2.1 million ($0.6 million collaboration, $1.5 million grant), down from $29.4 million a year earlier ($25.5 million collaboration, $3.9 million grant), which Arcturus attributed to lower CSL Seqirus revenue as milestones taper and the company pivots from infectious-disease vaccine work. This distinction matters: collaboration and grant revenue is partner- and government-funded, not direct product sales, since KOSTAIVE distribution runs through CSL Seqirus and the Meiji-led ARCALIS venture rather than Arcturus itself. For fiscal 2025, total revenue was $82.0 million ($67.2 million collaboration, $14.8 million grant), down from $152.3 million in fiscal 2024.
Spending, Losses and the Cash Runway
R&D expense fell to $21.5 million in the first quarter of 2026 from $34.9 million a year earlier as LUNAR-COVID costs declined, offset by higher LUNAR-OTC costs. G&A expense fell to $9.5 million from $11.3 million, and total operating expenses were $31.0 million versus $46.2 million. Net loss widened to $27.0 million, or $0.95 per share, from $14.1 million, or $0.52 per share. For fiscal 2025, R&D expense was $112.2 million (down from $195.2 million) and net loss was $65.8 million (versus $80.9 million in 2024). Cash and restricted cash totaled $213.4 million at March 31, 2026, down from $232.8 million at year-end 2025. Arcturus discloses no funded debt and says existing cash extends its runway into the second quarter of 2028.
What Could Move the Stock From Here
The nearest-term catalyst is data from the ongoing 12-week Phase 2 study of ARCT-032. On OTC deficiency, the end-of-Phase-2 meeting planned for the second half of 2026 should clarify the design of a pivotal pediatric study for ARCT-810. Meiji's KOSTAIVE rollout and BARDA-funded flu data could add modest partner revenue, though neither is a primary growth driver.
Risks Specific to Arcturus's Rare-Disease Pivot
Arcturus's near-term profile now depends on binary clinical readouts rather than diversified commercial revenue. A disappointing Phase 2 result for ARCT-032 would likely delay or unwind the Thermo Fisher arrangement, which is explicitly contingent on positive data. ARCT-810 still needs dosing data before a pivotal study can begin, and pediatric regulatory timelines are hard to predict. Collaboration revenue tied to CSL Seqirus and BARDA could keep declining, removing a funding cushion as clinical costs rise. The company also disclosed an ongoing lawsuit against AbbVie Inc. and Capstan Therapeutics, Inc., filed September 2025, with an unresolved outcome.
Outlook
An upside scenario has positive Phase 2 data validating the inhaled mRNA approach and activating the Thermo Fisher Phase 3 arrangement, giving Arcturus a second potential product beyond KOSTAIVE. A base case has Arcturus managing its roughly $213 million cash position while both programs advance through 2026 milestones and collaboration revenue keeps tapering. A downside scenario has a Phase 2 miss or faster revenue erosion compressing the runway sooner than projected. This article makes no prediction about share-price direction.
Conclusion
Arcturus Therapeutics Holdings Inc. (ARCT) enters the second half of 2026 in transition: KOSTAIVE still generates partner-funded revenue but at a declining rate, while ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency have become the central investment thesis. The Thermo Fisher collaboration signals commercial-readiness planning, but remains conditional on Phase 2 success. With net losses widening and revenue shrinking faster than expenses, ARCT's roughly two-year cash runway leaves limited room for setbacks.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...